VentiRX cancer vax wins fast-track status, financing; Canadian Ebola vaccines held up in Winnipeg;

> The day after announcing it had won fast-track status for its cancer vaccine and raised a new round of cash to fund a trial of the candidate, VentiRx announced it had partnered up on a new immuno-oncology combo development effort with AstraZeneca's ($AZN) checkpoint inhibitor MEDI-4736. More

> PaxVax has appointed Mark Meltz as EVP and chief legal officer. Release

> The Gates Foundation has awarded Oregon scientists $25 million for HIV vaccine research. Report

> The National Institute of Allergy and Infectious Diseases (NIAID) has provided $2.4 million in funding to BioCryst Pharmaceuticals ($BCRX) for further development of a potential vaccine to treat Ebola. More

And Finally... Three weeks after it was offered to Africa to fight the deadly epidemic there, Canada's experimental Ebola vaccine was held up in the government lab that developed it as officials tried to decide how to safely transport it. Report